Loading...
Market
What will be Gilead's pricing strategy for lenacapavir by mid-2025?
2
Resolution / Starting Odds
Uniform pricing across all markets • 25%
Tiered pricing based on market income levels • 25%
Significant discounts in low-income countries • 25%
Other pricing strategy • 25%
Gilead's official pricing announcements and market reports
Story
Gilead's Lenacapavir Injection Shows 96% Effectiveness in HIV Prevention, But Cost Poses Challenge
Nov 30, 2024, 04:25 AM
Recent clinical trials have shown that lenacapavir, an active ingredient developed by Gilead, significantly reduces the risk of HIV infection. Administered through a twice-yearly injection, the drug has demonstrated a 96% effectiveness rate in preventing HIV, potentially outperforming traditional oral pre-exposure prophylaxis (PrEP). This breakthrough has been described as a 'great relief' and could revolutionize HIV prevention strategies. However, the high cost of lenacapavir might pose a challenge to its widespread adoption in the fight against the disease.
View original story
Similar markets
Less than $50 annually • 25%
$50 to $100 annually • 25%
$100 to $500 annually • 25%
More than $500 annually • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $10,000 per year • 25%
$10,000 - $20,000 per year • 25%
$20,000 - $30,000 per year • 25%
Above $30,000 per year • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Global Fund • 25%
PEPFAR • 25%
Gilead Sciences • 25%
Other • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Cost • 25%
Distribution • 25%
Regulatory approval • 25%
Adherence • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%